Piper Sandler Maintains Overweight on Aadi Bioscience, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Joseph Catanzaro has maintained an Overweight rating on Aadi Bioscience (NASDAQ:AADI) but has significantly reduced the price target from $30 to $5.
December 15, 2023 | 5:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Aadi Bioscience but lowered the price target from $30 to $5, indicating a significant revision of the stock's future valuation.
The substantial decrease in the price target from $30 to $5 by a reputable analyst firm like Piper Sandler suggests a major reassessment of Aadi Bioscience's valuation, which could lead to a negative investor sentiment and a potential decline in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100